Free Trial

OmniAb Q2 2024 Earnings Report

OmniAb logo
$3.73 -0.03 (-0.80%)
(As of 12:32 PM ET)

OmniAb EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.18
Beat/Miss
Beat by +$0.05
One Year Ago EPS
-$0.15

OmniAb Revenue Results

Actual Revenue
$7.61 million
Expected Revenue
$6.52 million
Beat/Miss
Beat by +$1.09 million
YoY Revenue Growth
N/A

OmniAb Announcement Details

Quarter
Q2 2024
Time
After Market Closes

Conference Call Resources

Trump’s Sending THIS Crypto Higher on Purpose (Ad)

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW

OmniAb Earnings Headlines

"X-Ray Vision" could find thousands of hidden market opportunities
Let me show you how I trade with “X-Ray vision.” You see, most “trend” traders only use one trend filter when looking for an optimal buy signal. And that can be a big mistake because you can’t see if you’re in a “True Trend.” But my newest trading tool is designed to only target the best, most stable stocks… Using 3 trend filters… which are these green, yellow, and red lines.
Stifel Nicolaus Keeps Their Buy Rating on OmniAb (OABI)
See More OmniAb Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OmniAb? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OmniAb and other key companies, straight to your email.

About OmniAb

OmniAb (NASDAQ:OABI), a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

View OmniAb Profile

More Earnings Resources from MarketBeat

Upcoming Earnings